Combination empiric therapy with voriconazole and lipid amphotericin B formulation recommended, especially for severe infection or immunocompromised, until speciation and susceptibilities available.

Therapeutic drug monitoring (TDM) recommended after 5 days – target trough 1-5.5µg/mL.